These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 24058440

  • 1. Fusion protein vaccines targeting two tumor antigens generate synergistic anti-tumor effects.
    Cheng WF, Chang MC, Sun WZ, Jen YW, Liao CW, Chen YY, Chen CA.
    PLoS One; 2013; 8(9):e71216. PubMed ID: 24058440
    [Abstract] [Full Text] [Related]

  • 2. Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.
    Peng S, Ferrall L, Gaillard S, Wang C, Chi WY, Huang CH, Roden RBS, Wu TC, Chang YN, Hung CF.
    mBio; 2021 Jan 19; 12(1):. PubMed ID: 33468698
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
    Li YL, Qiu XH, Shen C, Liu JN, Zhang J.
    Oncol Rep; 2010 Nov 19; 24(5):1323-9. PubMed ID: 20878127
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. HPV16 mutant E6/E7 construct is protective in mouse model.
    Goodarzi MM, Mosayebi G, Ganji A, Raoufi E, Sadelaji S, Babaei S, Abtahi H.
    BMC Biotechnol; 2024 Sep 30; 24(1):71. PubMed ID: 39350162
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Genetically modified cellular vaccines for therapy of human papilloma virus type 16 (HPV 16)-associated tumours.
    Bubenik J.
    Curr Cancer Drug Targets; 2008 May 30; 8(3):180-6. PubMed ID: 18473731
    [Abstract] [Full Text] [Related]

  • 10. A Chlamydomonas-derived Human Papillomavirus 16 E7 vaccine induces specific tumor protection.
    Demurtas OC, Massa S, Ferrante P, Venuti A, Franconi R, Giuliano G.
    PLoS One; 2013 May 30; 8(4):e61473. PubMed ID: 23626690
    [Abstract] [Full Text] [Related]

  • 11. A novel "priming-boosting" strategy for immune interventions in cervical cancer.
    Liao S, Zhang W, Hu X, Wang W, Deng D, Wang H, Wang C, Zhou J, Wang S, Zhang H, Ma D.
    Mol Immunol; 2015 Apr 30; 64(2):295-305. PubMed ID: 25575128
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Immuno-Stimulating Peptide Derived from HMGB1 is More Effective Than the N-Terminal Domain of Gp96 as an Endogenous Adjuvant for Improvement of Protein Vaccines.
    Talebi S, Bolhassani A, Azad TM, Arashkia A, Modaresi MH.
    Protein Pept Lett; 2017 Apr 30; 24(3):190-196. PubMed ID: 28000571
    [Abstract] [Full Text] [Related]

  • 19. GTL001 and bivalent CyaA-based therapeutic vaccine strategies against human papillomavirus and other tumor-associated antigens induce effector and memory T-cell responses that inhibit tumor growth.
    Esquerré M, Momot M, Goubier A, Gonindard C, Leung-Theung-Long S, Misseri Y, Bissery MC.
    Vaccine; 2017 Mar 13; 35(11):1509-1516. PubMed ID: 28196735
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.